All Drug Development articles – Page 3
-
NewsLab-made lncRNA could lead to new anti-inflammatory drugs
Scientists at the University of Toronto have created long noncoding RNA outside living cells for the first time, a breakthrough that has already produced experimental anti-inflammatory molecules.
-
ArticleNavigating IND delays: strategic options for early-phase biotech development
As IND timelines lengthen, early-stage biotechs face growing uncertainty in early clinical planning. This article explores how sponsors are increasingly diversifying their development strategies and why New Zealand represents an attractive option.
-
NewsNew target found for glaucoma treatment
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
-
ArticleWorld ADC 2026: where antibody-drug conjugates are heading
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
-
NewsNew AI tool could accelerate drug discovery and cut lab costs
Scientists have developed a machine learning system that can predict how complex chemical reactions will produce the correct molecular form for medicines.
-
NewsARK1 identified as target for future malaria drugs
Scientists have identified Aurora-related kinase 1 (ARK1) as a vital protein in malaria parasite development, a breakthrough that could enable future drugs designed to block transmission.
-
NewsCircular RNA drives 50-fold boost in eye gene therapy
New in vivo data show a circular RNA platform can deliver up to a 50-fold increase in gene expression in the eye compared with conventional mRNA-based AAV approaches.
-
NewsBispecific EGFR/EphA2-targeting ADC shows promise in colorectal cancer
Promatix Biosciences Ltd has announced positive preclinical data for its first-in-class bispecific antibody–drug conjugate, PBS293-MMAE, demonstrating enhanced tumour selectivity, improved suppression and reduced toxicity in colorectal cancer models.
-
NewsTargeting senescent cells may reduce postpartum breast cancer risk
A study from the Institut Pasteur reveals how cellular senescence during mammary gland involution after pregnancy may both aid tissue repair and promote postpartum breast cancer.
-
News$3.2m project targets aggressive MDM2 in breast cancer
A University of Houston scientist has joined a $3.2 million research collaboration to develop a new drug targeting one of the key drivers of triple-negative breast cancer.
-
NewsAMD3100 drug could boost immunotherapy in rare liver cancer
A rare liver cancer that primarily affects young people may soon have a new treatment option, after researchers found that an existing FDA-approved drug could enable immunotherapy to work effectively against tumours.
-
ArticleEngineering the next generation of T-cell engagers
T-cell engagers are a branch of immunotherapy that has undergone considerable change since their clinical inception. Andrew J Souers, VP, Oncology Discovery Research at AbbVie, elucidates the current understanding of their biology and expanding focus areas of application.
-
NewsNew OC-PAM AI tool tracks cancer organoid drug response
Scientists have developed an AI-enhanced imaging platform that enables non-invasive, label-free and longitudinal monitoring of cancer organoids and spheroids.
-
NewsNew SerpinB2 immune cell discovery could reverse type 2 diabetes
Researchers at the University of Pittsburgh School of Medicine have developed a new approach for tackling insulin resistance and type 2 diabetes by protecting beneficial immune cells in fat tissue.
-
OpinionAI in drug discovery: predictions for 2026
As AI drug discovery enters 2026, the industry faces a pivotal year of clinical tests, regulatory clarity, and market consolidation. Here, Dr Raminderpal Singh examines where AI is delivering measurable gains in early discovery, where hype outpaces reality and why Phase III results will determine whether the technology can truly ...
-
ArticleAI begins to enter Alzheimer’s drug discovery pipelines
Artificial intelligence is increasingly used to analyse large, multimodal Alzheimer’s datasets and inform target discovery and trial design. A new JPAD special issue highlights how these methods are moving from experimentation towards practical application in drug discovery.
-
NewsLaunaea herb could provide new treatments for peptic ulcers
A herb called Launaea nudicaulis could be used to treat peptic ulcers, with early research suggesting both gastroprotective benefits and potential applications in natural product drug discovery.
-
NewsDrug Target Review’s women in STEM
For International Day of Women and Girls in Science, Drug Target Review highlights articles published over the past year that were authored by women, celebrating their contributions to research.
-
NewsHDAC11 protein identified as potential target for Duchenne muscular dystrophy
A new preclinical study has shown that reducing the protein HDAC11 could slow muscle degeneration in Duchenne muscular dystrophy, providing a potential target for future therapies.
-
NewsNew paper warns against phasing out animal testing too quickly
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.